RadFollow
Sign in
Guideline Current ACR / ESUR / AdMeTech 2019

PI-RADS v2.1

Prostate Imaging Reporting and Data System v2.1 for multiparametric prostate MRI. Assessment categories 1 (clinically significant cancer very unlikely) through 5 (clinically significant cancer highly likely).

Structured reportUpdated Jul 5, 2026
Applies to
  • Treatment-naïve prostate multiparametric MRI
  • Detection of clinically significant prostate cancer
Classification
  • PI-RADS 1
  • PI-RADS 2
  • PI-RADS 3
  • PI-RADS 4
  • PI-RADS 5
Exclusions
  • Post-treatment prostate (radiation, focal therapy, prostatectomy)
  • Known metastatic prostate cancer surveillance
Interactive

Decision tree

Enter a finding to compute a recommendation without leaving the page.

Recommendation builder

Select the PI-RADS assessment category.

Evidence

References

  1. PrimaryTurkbey B, et al. Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of PI-RADS Version 2. Eur Urol. 2019;76(3):340-351.
FAQ

Frequently asked

Does this guideline apply to oncology patients?

No — patients with known malignancy fall outside the scope unless the guideline states otherwise. Follow oncologic surveillance protocols instead.